Interleukin-17A drives joint chondrocyte senescence through mitochondrial dysfunction in mice
Blocking the cytokine with secukinumab reduced cartilage senescence and slowed osteoarthritis progression in a mouse model.
Oral diseases · Zhu M et al. · Paper published 30 Sep 2026
In a study of mice, researchers investigated how interleukin-17A drives chondrocyte senescence in temporomandibular joint osteoarthritis. The team modeled the joint condition using unilateral anterior crossbite and observed that cartilage senescence rose alongside interleukin-17A levels. In cultured mouse ATDC5 chondrocytes, interleukin-17A exposure prompted cellular senescence. The cytokine elevated STAT3 phosphorylation, which raised levels of the mitochondrial fusion protein OPA1. This response caused mitochondrial hyperfusion, generated mitochondrial reactive oxygen species, and impaired mitochondrial function. When the authors treated mice with the anti-interleukin-17A antibody secukinumab, the therapy lowered chondrocyte senescence and suppressed joint disease progression.
Why it matters
The findings define a specific inflammatory pathway linking mitochondrial dysfunction to chondrocyte senescence and identify interleukin-17A as a potential therapeutic target in joint disease.
Caveats
The experiments were conducted in mice and in vitro mouse cell cultures, meaning human trials are required to test clinical efficacy.
Written from the paper’s abstract, and every claim checked against it before publishing. Read the paper for the full methods and data.
The paper
IL-17A Induces Chondrocyte Senescence via the STAT3-OPA1-mtROS Axis in Temporomandibular Joint Osteoarthritis
Zhu M, Zhang C, Zhang Y et al.
Oral diseases · 30 Sep 2026 · Peer-reviewed
- Relevance
- Relevant
- News value
- Notable
- Evidence
- Animals
- Status
- Peer-reviewed
More on Cellular senescence
See allDasatinib and quercetin reduce liver fibrosis in a phase-2 MASH trial
The senolytic combination improved liver fibrosis without disease worsening in nearly half of treated participants while lowering cellular senescence markers.
Nature metabolism · Koning M et al.
A distinct p21-driven macrophage senotype accumulates during aging and liver disease
Researchers identified a p53-p21-Cyclin D2 axis that governs senescent macrophages in mice and human liver cirrhosis and can be cleared with senolytics.
bioRxiv · Torres G et al.
DNA methylation proxies of senescence markers track human disease and mortality
The new blood-based tools estimate senescence gene activity to predict incident diseases, all-cause mortality, and clinical treatment responses.
medRxiv · Simpson DJ et al.
Bispecific T cell engager eliminates senescent cells in mice and nonhuman primates
Monitored by serum transaminase levels, low doses of the drug alleviated age-related pathologies without causing the hepatotoxicity seen at higher doses.
Aging cell · Deng J et al.
A deep learning score for cellular senescence predicts human mortality and disease risk
The proteomic biomarker tracked chronic illness risk in the UK Biobank and shifted following an 18-month multimodal exercise intervention.
Aging cell · Zhao S et al.